Corporate Presentation Developing the Next Generation of Targeted Therapies Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective's pipeline and platform has the potential to significantly ex

Corporate Presentation

Developing the Next Generation of Targeted Therapies

Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective's pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT

Perspective's Innovative Platform

Perspective's Radiopharmaceutical Platform Optimized for a Broader Therapeutic Window

Proposed Mechanism of Action for 212Pb

Perspective's Proprietary Chelator Has Been Optimized for Lead-Based RPTs

Perspective's Pre-Targeting Platform

Supply Chain and Manufacturing Infrastructure

On-Demand Order Fulfillment at Regional Sites to Deliver Finished Products

Neuroendocrine Tumors: VMT- -NET

Trial Design: [212Pb]VMT- -NET Phase 1/2a For Neuroendocrine Tumors

Signal of Sustained Anti-Tumor Activity

[212Pb]VMT- -NET Was Well Tolerated

No Decline in Renal Function Observed

Patient with PR after [212Pb]VMT- -NET

Melanoma Program: VMT01/02

Trial Design: [212Pb]VMT01 Phase 1/2a For Metastatic Melanoma

Treatment Emergent Adverse Events (occurring in 2 patients and/or Grade 2)

PSV359 is Active Against FAP- Expression on Tumor and on Stroma

General Corporate Information